sample review
- Biogenex anti-CD44 antibody was used to perform immunohistochemistry in order to find out what activities of human thyroid cancer stem cells could be potential targets to treat thyroid carcinoma.
- BioGenex anti-Cdx2 antibody was used to perform immunocytochemistry in order to study the function of the Cdx2 in early mammalian embryonic development.
- BioGenex anti-CDX2 antibody was used to perform immunohistochemistry in order to study CDX2 mutation in gastric cancer.
- BioGenex anti-CDX2 monoclonal antibody (CDX2-88, 1:200) was used to perform immunohistochemistry and immunofluorescence staining in order to study squamous differentiation in endometrial lesions.
- Biogenex anti-Cdx2 antibody was used to perform immunohistochemistry and western blot in order to study the Cdx2 regulated epithelial cell polarity and morphogenesis.
- Biogenex anti-ITGB1 (AM298-5 M MU298-UC) antibody was used to perform immunohistochemistry/immunocytochemistry in order to study the altered expression levels of metastasis-related plasma membrane proteins of human breast cancer cells.
- BioGenex Super Sensitive IHC Detection System was used to carry out immunohistochemistry assays in order to investigate the mechanism for CEA-binding bacteria counteracting shedding of epithelial cells.
- Biogenex anti-human mitochondrial antigen antibody was used for immunohistochemistry in order to demonstrate that in Parkinson's disease, a novel transferrin/TfR2-mediated mitochondrial iron transport system was disrupted
- BioGenex Concentrated Detection System was used to perform immunohistochemistry in order to reveal viral oncoprotein E6 regulates the expression of tumor-suppressive miR-34a in cervical cancer-derived cell lines containing oncogenic HPVs.
- BioGenex anti-CDX2 antibody was used to perform immunohistochemistry in order to show that Cd1d plays an important role in regulating bacterial colonization in the intestine of mice.
- BioGenex blocking solution was used to block nonspecific binding in order to illustrate that anthracycline chemotherapy can inhibit the transcription of HIF-1 as well as the mobilization of circulating angiogenic cells in tumor.